CJC-1295 + Ipamorelin: Why Are They Combined? What the Research Shows

Two Different Receptor Pathways

CJC-1295 is a GHRH (growth-hormone-releasing hormone) analog and directly stimulates the pituitary's GHRH receptor – this provides sustained baseline stimulation of the body's own GH production.

Ipamorelin acts via a different receptor: the ghrelin receptor (GHS-R). The foundational study (Raun et al., 1998) describes ipamorelin as the first highly selective GH secretagogue – unlike older GH-releasing peptides, in this study it did not trigger a relevant additional release of ACTH or cortisol.

Where the Synergy Assumption Comes From

The idea of combining GHRH analogs with ghrelin receptor agonists rests on a classic human study by Bowers et al. (1990, Journal of Clinical Endocrinology & Metabolism): in healthy men, co-administration of GHRH and the GH-releasing hexapeptide GHRP produced substantially greater GH release than either compound alone – an additive or synergistic effect of two independent signaling pathways.

Important for context: this study tested GHRH plus the original GHRP hexapeptide – not CJC-1295 and not ipamorelin. It establishes the mechanistic logic of the drug classes but is not direct evidence for these two specific molecules.

What's Missing for This Specific Combination

Based on current research, no published randomized human study specifically examines CJC-1295 and ipamorelin in combination. The synergy assumption rests on (a) the general receptor-class logic from the Bowers study and related research, and (b) the separately documented individual profiles of both compounds – not on direct combination data.